论文部分内容阅读
作者在25名 HIV 和 HBsAg 血清阴性,身体健康的男子中进行免疫试验,完成了第一阶段抗 HIV-1型人类免疫缺陷病毒疫苗的工作。试验所用抗原 env2-3(SFI)是由基因Ⅰ程制得的一种非糖苷健连接、不与 CD_4端结合的变性多肽,分子量约56,000,纯度在95%以上。其结构相似于 HIV-1分离株外膜蛋白 gp120区域。所用佐剂 MTP-PE 为一种人工合成的亲脂性的胞壁酰三肽。25名20到60岁受试者随机分成五组。第一、二组共10人作为对以组接种佐剂100μg,时间分别为
The authors conducted an immunoassay in 25 HIV-positive and HBsAg-seronegative, healthy men and completed the first phase of the anti-HIV-1 human immunodeficiency virus vaccine. The antigens env2-3 (SFI) used in the experiment is a non-glycosidic linked non-CDg-binding modified denatured polypeptide produced by the gene I program. It has a molecular weight of about 56,000 and a purity of over 95%. Its structure is similar to the HIV-1 isolate outer membrane protein gp120 region. The adjuvant MTP-PE used is a synthetic lipophilic muramyl tripeptide. Twenty subjects aged 20 to 60 years were randomly assigned to five groups. First, two groups of 10 people as the group vaccination adjuvant 100μg, respectively, time